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Abstract 
Background Neurotrophic factors are endogenous proteins promoting the survival of different neural cells. Therefore, they 
elicited great interest as a possible treatment for neurodegenerative disorders, including Parkinson’s Disease (PD). PD is the 
second most common neurodegenerative disorder, scientifically characterized more than 200 years ago and initially linked 
with motor abnormalities. Currently, the disease is viewed as a highly heterogeneous, progressive disorder with a long 
presymptomatic phase, and both motor and non-motor symptoms. Presently only symptomatic treatments for PD are avail-
able. Neurohistopathological changes of PD affected brains have been described more than 100 years ago and characterized 
by the presence of proteinaceous inclusions known as Lewy bodies and degeneration of dopamine neurons. Despite more 
than a century of investigations, it has remained unclear why dopamine neurons die in PD.
Methods This review summarizes literature data from preclinical studies and clinical trials of neurotrophic factor based 
therapies for PD and discuss it from the perspective of the current understanding of PD biology.
Results Newest data point towards dysfunctions of mitochondria, autophagy-lysosomal pathway, unfolded protein response 
and prion protein-like spreading of misfolded alpha-synuclein that is the major component of Lewy bodies. Yet, the exact 
chain of events leading to the demise of dopamine neurons is unclear and perhaps different in subpopulations of patients.
Conclusions Gaps in our understanding of underlying disease etiology have hindered our attempts to find treatments able 
to slow down the progression of PD.
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Abbreviations
6-OHDA  6-Hydoxydopamine
ARTN  Artemin
ASK1  Apoptosis signal-regulating kinase 1
ATF4  Activating transcription factor 4
ATF6  Activating transcription factor 6
BCL-2  B-cell lymphoma 2 anti-apoptotic protein
BDNF  Brain-derived neurotrophic factor
BiP  Binding immunoglobulin protein
Caspases  Cysteine-containing proteases that cleave 
substrates after aspartic acid
CDNF  Cerebral dopamine neurotrophic factor
CHOP  C/EBP homologous protein
eIF2A  Eukaryotic translation initiation factor 2A
EC  Encapsulated cell
ER  Endoplasmic reticulum
GBA  β-Glucocerebrosidase
GDNF  Glial cell line-derived neurotrophic factor
GFRα (1–4)  GDNF Family Receptor alpha (1–4)
GFLs  GDNF family ligands
GPI  Glycosylphosphatidylinositol
IRE1α  Inositol-requiring protein 1
LP  Lewy pathology
MANF  Mesencephalic astrocyte-derived neuro-
trophic factor
MAPK  Mitogen-activated protein kinase
MPTP  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine
NCAM  Neural Cell Adhesion Molecule
NF-κB  Nuclear Factor Kappa-light-chain-enhancer 
of activated B cells
Nrf2  Erythroid 2-related factor 2
1197Neurotrophic factors for disease-modifying treatments of Parkinson’s disease: gaps between…
1 3
NRTN  Neurturin
NTFs  Neurotrophic factors
PD  Parkinson’s disease
PI3K  Phosphatidylinositol-4,5-bisphosphate 
3-kinase
PERK  Protein kinase RNA-like ER kinase
PET  Positron emission tomography
PSPN  Persephin
PFFs  α-Synuclein preformed fibrils
SNpc  Substantia nigra pars compacta
SPECT  Single photon emission computed 
tomography
Trk  Tyrosine kinase receptor
UPR  Unfolded protein response
XBP1  X-box binding protein 1
Introduction
Despite numerous efforts, treatments capable of slowing 
down the progression of Parkinson’s disease (PD) are still 
unavailable. Neurotrophic factor (NTF)-based therapies for 
PD hold great promise, yet they have so far failed to enter 
the clinic. Technical limitations, such as incomplete delivery 
protocols, difficulties in selection of the optimal NTF, and its 
dose, might explain unsatisfactory results with NTFs in PD 
clinical trials. Furthermore, poor understanding of disease 
etiology and progression and subsequently, an inadequate 
clinical trial design, might also have played a significant 
role. Moreover, our knowledge of the NTFs’ effects on dopa-
mine neurons, especially in the aging, diseased brain, is also 
limited. In this review, we are aiming to outline the current 
state of knowledge about PD and molecular processes lead-
ing to the degeneration of dopamine neurons and consider 
implications for the development of disease-modifying ther-
apies for PD. Subsequently, we also summarize preclinical 
and clinical studies with NTFs in PD, taking into account 
how they relate to our fundamental understanding of the 
disease.
What is Parkinson’s disease?
PD is neurodegenerative disorder affecting about 10 million 
people worldwide. PD prevalence ranges from 10–1500 per 
100,000 depending on the population. The highest preva-
lence is in Europe and North America and the lowest in 
Africa and Asia [1] with a higher incidence in males than 
females [1]. The most significant risk factor for PD is age 
[1]. Other reported risk factors include pesticide expo-
sure and rural living [1, 2]. Additionally, about 5–10% 
of PD cases are familial forms linked with chromosomal 
regions named in chronological order PARK1, PARK2, 
PARK3, etc.[2]. Monogenic forms of PD account for 3–5% 
of total PD cases. They are caused by mutations in more 
than a dozen genes such as SNCA (PARK1/4) (encoding 
α-synuclein), Parkin (PARK2), PINK1 (PARK6), DJ-1 
(PARK7), LRRK2 (PARK8), ATP13A2 (PARK9), VPS23C 
(PARK23), etc.[2]. Moreover, mutations in GBA gene encod-
ing β-glucocerebrosidase (GBA) is the greatest genetic risk 
factor for PD [2, 3].
Classic symptoms of PD are motor abnormalities like 
resting tremor, bradykinesia, postural instability, and muscle 
rigidity [2], caused by the death of dopamine neurons in the 
substantia nigra pars compacta (SNpc). This neuronal loss 
begets dopamine deficiency in the basal ganglia leading to 
observed abnormalities in motor functions. Dopamine defi-
ciency regulation is also the main target of currently avail-
able treatments either through promoting the synthesis of 
dopamine, inhibiting dopamine degradation, or direct acti-
vation of dopamine receptors. Such symptomatic treatments 
of PD are very effective in the early and middle stages of 
disease progression [2]. However, the underlying neurode-
generation advances slowly but inexorably, leading to wors-
ening of the patients’ condition, decreased responsiveness to 
symptomatic treatment, eventually causing death preceded 
by phase with severe frequent falls, severe dementia and hal-
lucinations [2]. Knowing that death of SNpc dopamine neu-
rons is a prominent neuropathological feature of PD, it was 
not surprising that neurotrophic factors (NTFs), with their 
strong survival-promoting action on neurons, elicited high 
hopes for the neuroprotective treatment. However, while 
initial preclinical studies demonstrated excellent efficacy of 
trophic factors in animal models, none of these treatments 
have so far entered the clinic [4].
Motor and non‑motor symptoms of PD
Motor symptoms have been associated with PD since its ini-
tial description more than 200 years ago and still constitute 
the bulk of PD diagnosis criteria [5]. These are bradykinesia 
(slowness in the initiation of motion), rigidity, resting trem-
ors, and postural instability. Apart from motor features, it is 
increasingly recognized that a plethora of non-motor symp-
toms are occurring in PD. These include constipation, sleep 
disturbances, anosmia, and increased incidence of depres-
sion [2]. In later stages of the disease progression, addi-
tional symptoms such as cognitive impairment, fatigue, pain, 
orthostatic hypotension, and urinary problems develop [2]. 
Importantly, some of the aforementioned non-motor symp-
toms precede motor symptoms, and their diagnosis indicates 
the pre-symptomatic phase and progressive character of the 
disease. The linkage between non-motor features of PD and 
degeneration of dopamine neurons remains, in most cases, 
unclear. Non-motor symptoms do not respond to dopamine 
replacement therapies [2], and conversely, it is unknown if 
they will be alleviated by NTFs or other disease-modifying 
1198 P. Chmielarz, M. Saarma 
1 3
therapies aimed to increase SNpc dopamine neuron survival. 
However, gastrointestinal problems have been linked to the 
loss of enteric dopamine neurons and the presence of Lewy 
pathology in the enteric nervous system [6]. Interestingly, 
cerebral dopamine neurotrophic factor (CDNF)-deficient 
mice develop an age-dependent loss of enteric neurons that 
occurs selectively in the submucosal but not in the myenteric 
plexus. The deficits in enteric neurons are reflected function-
ally in delayed gastric emptying, slowed colonic motility, 
and prolonged total gastrointestinal transit. The selective 
vulnerability of enteric neurons to the absence of CDNF is 
reminiscent of the tendency of pathological abnormalities to 
occur in the gastrointestinal tract in biopsies of patients with 
PD [7]. Moreover, GDNF and NRTN also have a prominent 
effect on the development and maintenance of enteric neu-
rons [8].
Progression of Parkinson’s disease
It is currently believed that a complex interplay between 
environmental factors and genetic predispositions is respon-
sible for PD development. The age seems to be the strongest 
risk factor of the disease [1]. However, it is now commonly 
accepted that PD starts many years before its clinical diag-
nosis [2]. Motor symptoms, which are the hallmark of PD, 
manifest when degeneration and loss of dopamine neurons 
are already reaching at least 30%, albeit some estimates are 
as high as 60% [9, 10]. Neurodegeneration progresses rap-
idly after the initial diagnosis, with majority of the SNpc 
dopamine neurons lost within 4–5 years [9]. Advanced 
neurodegeneration at the time of diagnosis and its fast pace 
afterward has far-reaching implications for the develop-
ment of treatment strategies for PD. Drugs that would slow 
down or stop the neurodegeneration should be administered 
immediately after diagnosis, or preferentially even during 
the presymptomatic period. The prodromal period, before 
the onset of motor symptoms and implicitly before signifi-
cant loss of dopamine neurons, can be as long as ten years 
or even more [2, 10]. This time could be a window of oppor-
tunity where treatments, even modestly slowing down the 
pace of neurodegeneration, could have a significant impact 
on treatment outcome. However, actual clinical trial design 
for NTF-based therapies has followed the opposite strategy. 
NTFs were administrated mainly to relatively late-stage 
patients (Fig. 1), to minimize the risk involved with com-
plicated brain surgery and because of the problems related 
to the diagnosis of PD. Early diagnosis of PD is not trivial. 
Its base is mainly on the presence of bradykinesia and at 
least one of the other motor features (rigidity, resting tremor, 
and postural instability) [2]. Importantly, these symptoms 
are not specific, and other underlying conditions have to be 
excluded, while additional criteria such as responsiveness 
to dopamine replacement therapy and progressive character 
support a diagnosis of PD. Confidence in diagnosis is often 
gained only years after initial motor symptoms are observed. 
Traditionally, confirmation of PD diagnosis can be obtained 
by histopathological examination of post-mortem brain 
samples by finding Lewy bodies and assessing dopamine 
neuron degeneration [2, 11]. Quantification of dopamine 
neuron degeneration is also possible through single photon 
emission computed tomography (SPECT) or positron emis-
sion tomography (PET), however these expensive imaging 
techniques are not yet routinely used in the clinic for PD 
diagnosis [2].
Histopathological features of PD
The healthy human brain has in both hemispheres in the 
SNpc about 0.5 million dopamine neurons. The main patho-
logical finding in the PD affected brain is the loss of dopa-
mine neurons in the SNpc and their projections to caudate 
putamen [11]. Patients with an initial diagnosis already 
show significant degeneration and loss of these neurons [9, 
10]. While dopamine neurons in the SNpc have been the 
main target of treatments aimed to stop neurodegeneration, 
it is important to remember that other brain areas are also 
affected. Neurodegeneration linked with PD is observed in 
the amygdala, hypothalamus, raphe nucleus, and locus coer-
uleus [12]. It is currently unclear how neurodegeneration 
regions other than the SNpc area contribute to the motor and 
non-motor symptoms or whether it could affect the degen-
eration of dopamine neurons. Although it was suggested that 
the loss of noradrenergic stimulation from locus coeruleus 
could make dopaminergic cells more prone to degeneration 
[13].
The second characteristic histopathological feature of 
PD is the presence of Lewy pathology (LP) in the form of 
insoluble proteinaceous aggregates found in neuronal soma 
(Lewy bodies) and processes (Lewy neurites) [14]. The pro-
tein α-synuclein was demonstrated to be the main compo-
nent of these aggregates [14]. Spreading of LP through the 
brain was proposed to correspond to clinical stages of the 
disease [15], and curiously, it seems to follow neuronal con-
nections [12]. There is mounting evidence that α-synuclein 
can spread through neuronal networks in a prion-like fashion 
[16].
However, while Lewy pathology has convincingly been 
shown as a biological marker of PD, its causative role is 
far from being proven. Actually, in a subset of patients 
with familial forms of PD, LP was not found in post-mor-
tem brain examinations [17]. Moreover, Lewy bodies and 
Lewy neurites can also be found in some patients without 
diagnosed PD [5]. The process of LP formation, and their 
contribution to the degeneration of dopamine neurons, 
is yet to be fully elucidated. Nonetheless, ways of stop-
ping transmission of α-synuclein, and thus preventing the 
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spreading of LP, are intensively pursued in the hope that 
they would stop disease progression.
Another pathological feature found in PD patient brains 
are signs of ongoing neuroinflammation i.e., markers of 
reactive astrocytes and microglia [18], indicating a non-
cell autonomous mechanism involved in neuronal death in 
PD. Through the release of pro-inflammatory cytokines 
and reactive oxygen species, reactive astrocytes and 
microglia could be directly damaging dopamine neurons. 
Alternatively, triggering their inflammatory activation 
could lead to decreased neurotrophic support they nor-
mally provide [18]. However, it remains unclear whether 
neuroinflammation is a proximal or distal phenomenon, 
how significant is its contribution to dopamine neuron 
demise, and if it might also have some protective role.
Heterogeneity of PD
Adding to the complexity of PD is the fact that both motor 
and non-motor symptoms of PD exhibit heterogeneity 
among patients. There have been several attempts to clas-
sify different subtypes of PD, but until now, no general 
agreement has been made [19]. Subtypes of PD have dif-
ferent rates of disease progression and might not share the 
same etiology [20]. Such a notion is in line with a multi-
tude of diverse environmental and genetic risk factors for 
PD. Understandably, this might have major implications 
for clinical trial outcomes, suggesting that PD patients 
might require a more personalized approach, targeting 
treatment to specific pathological processes which could 
drive PD progression only in a subset of patients [21].
Fig. 1  Approximate time course of Parkinson’s disease (PD), putative 
treatment effectivness and clinical trial schedules. Age is the strong-
est risk factor for PD and accumulating pathological events in dopa-
mine neurons probably starts decades before the onset of the disease. 
Similarly, non-motor symptoms are present as long as 20 years before 
the diagnosis of PD. At the time of motor symptoms and diagnosis, 
an already significant portion of dopamine neurons is lost. Sympto-
matic treatment enhancing the action of remaining neurons is still 
effective for several years, however these remaining neurons rapidly 
degenerate, and the effectiveness of the treatment diminishes. Based 
on preclinical data, NTF-based therapy would also be most effective 
immediately after diagnosis based on motor symptoms, or even bet-
ter if administered in the presymptomatic phase, however actual clini-
cal trials were performed in mid-to-late stage patients due to ethical 
issues
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Clinical features of PD and disease‑modifying 
treatments
Altogether, the existence of premotor symptoms up to 
10  years before diagnosis and the loss of a significant 
amount of dopamine neurons reported at the onset of 
motor symptoms imply advanced neuropathology already 
exists in what we call early PD. Moreover, loss of majority 
of dopamine neurons occurs within 5–7 years after diag-
nosis. Importantly, we do not know how advanced is the 
pathology at the cellular level in the remaining neurons at 
the time of diagnosis. These neurons may already be past a 
stage where targeting a single pathological process could 
restore cellular homeostasis. Similarly, drug trials targeting 
a single pathological mechanism would also be doomed to 
fail in a general patient population if PD heterogeneity is 
reflecting different underlying etiologies. In fact, multiple 
clinical trials targeting oxidative stress, which is widely 
accepted to be involved in PD, failed despite being tested 
in early-stage patients. The currently ongoing MOPES-PD 
trial (NCT02906020) targets the patient-specific mechanism 
(i.e. impaired glucocerebrosidase activity) in early stages 
of familial forms of PD. If successful, it would be strong 
support for patient-specific early-stage treatments. However, 
for personalized treatment of most patients, a test capable 
of distinguishing patient subpopulations, preferably at the 
pre-motor stage, would be required. Interestingly, mono-
amine oxidase (MAO) inhibitors rasagiline and selegiline 
have demonstrated modest disease-modifying effects when 
administered to early-stage patients [22, 23]. MAO inhibi-
tors seem to exert protective effects on dopamine neurons 
through multiple mechanisms, including stimulation of NTF 
signaling providing general survival-promoting cues [22]. 
However, this effect could not be fully disentangled from 
symptomatic effects, and the compounds are not officially 
recognized as disease-modifying agents [23].
At the same time, it is becoming increasingly clear that 
in late-stage PD patients, there is little hope for effective 
treatment, regardless if it is targeting specific pathological 
mechanisms or having a non-specific survival-promoting 
effect on neurons. Mostly due to the technical complications 
and resulting ethical concerns, NTF clinical trials for PD 
had been tested in mid-to-late stage patients unsuccessfully.
Apart from the quickly progressing demise of dopamine 
neurons it is worth considering that progressing pathology 
is not limited to SN dopamine neurons as exemplified by 
degeneration of noradrenergic neurons in locus coeruleus 
and the widespread presence of pathological protein aggre-
gates throughout PD patient brains. We do not know how 
much lasting improvement we can achieve if we try to rescue 
only dopamine neurons. In fact, it has even been suggested 
by pre-clinical data from us and others that loss of noradren-
ergic neurons might increase the susceptibility of dopamine 
neurons in the SN [13]. Furthermore, most non-motor 
symptoms of PD are unresponsive to dopamine replacement 
therapies suggesting that they arise from non-dopaminergic 
pathology. Therefore, non-motor symptoms will probably 
continue to progress even if we manage to stop degeneration 
of dopamine neurons successfully.
Disease etiology
Although PD symptoms and some treatments have been 
described in ancient Chinese and Indian documents even 
300–400 years BC, scientifically, PD had been described 
more than 200 years ago, and for more than 100 years we 
have known that progressive degeneration of dopamine neu-
rons is underlying its motor symptoms [24]. Yet, we still do 
not understand the molecular cause of their demise, and we 
know even less about the degeneration of other vulnerable 
populations of neurons.
Unique properties of dopamine neurons
Premature death of dopamine neurons in PD might be linked 
to their unique properties. First, the use of dopamine as the 
main neurotransmitter has been proposed as a potential lia-
bility. Dopamine easily oxidizes, and any defects in dopa-
mine storage inside intracellular vesicles could lead to oxida-
tive stress and, subsequently, mitochondrial and lysosomal 
dysfunction [25]. Another feature of dopamine neurons are 
very long and highly branched axons [26]. In mice, a single 
dopamine neuron innervates ~ 75,000 target neurons with a 
total length of axons in the striatum of almost 50 cm [26]. 
Therefore, activity of dopamine neurons requires a large 
amount of energy and maintaining a high level of intracellu-
lar trafficking and protein translation, especially of synaptic 
proteins such as α-synuclein. Moreover, the most vulnerable 
dopamine neurons in SNpc exhibit constant autonomous 
pacemaking activity [12]. It has been proposed that the reli-
ability of dopamine neuron firing is critical for the survival 
of an organism because it is involved in the rapid motor 
response to environmental challenges [12]. Therefore, evolu-
tion would favor reliability of firing even at the cost of faster 
“wear off” of cellular components. Accordingly, it would 
be more important to maintain high ATP production, even 
at the cost of occasionally generating increased oxidative 
stress. Similarly, maintaining protein translation would take 
precedence over maintaining protein homeostasis. In the 
long run, this could lead to an accumulation of damage and 
stochastic degeneration of individual neurons. Indeed dopa-
mine neurons seem to degenerate throughout our lifespan 
[10]. Because the threshold for the manifestation of motor 
PD symptoms is the loss of about 60% of dopamine neurons, 
an age-dependent loss would not be a problem during the 
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lifespan of most people. However, a lower initial number 
of neurons, increased rate of accumulating damage, or an 
additional pathological trigger putting strain on an already 
vulnerable and diminished population of dopamine neurons 
could precipitate the onset of PD [10].
Mitochondrial dysfunctions
Combined with the enormous synaptic network, autono-
mous pacemaking puts considerable energetic demands 
which strain mitochondria, potentially leading to mitochon-
drial damage and oxidative stress. Moreover, SNpc dopa-
mine neurons lack  Ca2+ buffering capacity [27], and their 
pacemaking activity is linked with large  Ca2+ fluctuations 
[28]. These  Ca2+ fluctuations modulate membrane potential 
and stimulate mitochondrial oxidative phosphorylation to 
maintain the required energy levels [29]. One side effect 
of pacemaking activity and  Ca2+ fluctuations in dopamine 
neurons is metabolic stress, which in the long run could lead 
to mitochondrial and lysosomal dysfunctions [29]. Support 
for the involvement of high calcium levels and mitochondrial 
dysfunction in PD is the fact that several PD-related genes 
are implicated in mitochondrial maintenance and turnover, 
and antioxidant defense (DJ-1, PINK1, Parkin) [2]. Addi-
tionally, damaged mitochondria and  Ca2+ fluctuations can 
affect the capacity of cells to deal with misfolded proteins 
[12, 30], which could make them more vulnerable to Lewy 
pathology. Conversely, Lewy pathology, or specifically the 
accumulation of misfolded or aggregated α-synuclein, was 
shown to impair mitochondrial function, autophagy, and 
calcium balance [31], potentially forming a vicious cycle.
Autophagy‑lysosomal pathway dysfunction
Dysfunctions in cellular degradative pathways that recycle 
unwanted or faulty cellular components like proteins (i.e. 
chaperone-mediated autophagy and ubiquitin–proteasome 
system) and organelles (i.e. macroautophagy) have also been 
implicated in PD pathology [32]. Mutations in PD-related 
genes LRRK2 and DJ-1 were shown to impair the autophagy-
lysosomal pathway [33] and a single allele mutation in the 
GBA gene encoding lysosomal enzyme GBA increases PD 
risk by five times [3]. Also, aggregated α-synuclein has been 
shown to impair the autophagy-lysosomal pathway [31]. 
Reciprocally, abnormalities in protein degradation pathways 
can lead to increased accumulation of misfolded α-synuclein 
[34]. A similar feedback loop might happen between mito-
chondrial dysfunction and macroautophagy since oxidative 
stress was reported to impair the latter, while impaired mac-
roautophagy would be detrimental for maintaining a healthy 
mitochondrial pool by slowing mitochondrial turnover [35].
ER stress and the unfolded protein response
Another important process linked with maintaining protein 
homeostasis and implicated in PD is endoplasmic reticu-
lum (ER) stress and activation of unfolded protein response 
(UPR) pathways [36]. ER stress and the UPR are cellular 
responses which strive to restore proteostatic balance by 
limiting new protein synthesis and increasing both chap-
erone activity and misfolded or aggregated protein degra-
dation [36]. While initially protective, UPR, if protracted, 
is detrimental especially to neuronal cells and can lead to 
apoptotic cell death. The UPR is activated upon an accu-
mulation of misfolded proteins in the ER lumen and their 
interaction with ER chaperone GPR78 protein (also known 
as binding immunoglobulin protein (BiP)). This leads to the 
dissociation of GPR78 from the ER membrane, where it 
normally binds three sensors of the UPR, triggering their 
activation (Fig. 2). These three UPR sensors are inositol-
requiring protein 1 (IRE1α), protein kinase RNA-like ER 
kinase (PERK), and activating transcription factor 6 (ATF6). 
IRE1α is the ER transmembrane serine-threonine kinase and 
the endoribonuclease degrading or splicing mRNAs near 
ER. Activated ATF6 acts as a transcription factor itself, 
while PERK phosphorylates eukaryotic translation initiation 
factor 2α subunit (eIF2α), reducing global translation except 
for specific mRNAs [36]. The transcription factor nuclear 
factor erythroid 2-related factor 2 (Nrf2) is the second PERK 
substrate, and it is a critical effector of PERK-mediated 
cell survival. Together these three arms of the UPR lead to 
downregulation of global protein synthesis with simultane-
ous upregulation of genes involved in protein folding, lipid 
biosynthesis, and protein degradation. Persistent activation 
of UPR leads to upregulation and activation of pro-apoptotic 
genes like transcription factor C/EBP homologous protein 
(CHOP), activation of apoptosis signal-regulating kinase 1 
(ASK1) and Nuclear Factor Kappa-light-chain-enhancer of 
activated B cells (NF-κB) and inhibition of anti-apoptotic 
B-cell lymphoma 2 (BCL-2) family members [37]. Moreo-
ver, prolonged reduction of protein synthesis can be espe-
cially detrimental to neuronal function [38].
Activation of the UPR has been demonstrated in post-
mortem PD patients’ brains [39] and linked with the accu-
mulation of misfolded α-synuclein [40], which can localize 
to the ER [41]. ER stress is also induced by many neurotox-
ins interfering with mitochondria action and used to model 
PD [42], suggesting a link to mitochondria dysfunction.
α‑synuclein and Lewy pathology
Multiplications of the α-synuclein gene cause a familial form 
of PD [43], supporting α-synuclein’s pathological potential 
in humans. We know that α-synuclein can exist in several 
different conformers in monomeric or oligomeric forms, as 
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well as in fibrils of different sizes and conformations [44]. 
Preclinical studies investigating the role of α-synuclein in 
PD utilized overexpression of α-synuclein [45] or more 
recently seeding of α-synuclein misfolding and aggregation 
with prion-like preformed α-synuclein fibrils (PFFs) [46] 
both in vitro and in animal models [16, 46]. In these models, 
α-synuclein overexpression, misfolding and/or aggregation 
was linked with dysfunctions of mitochondria, autophagy, 
intracellular transport, neurotransmitter release, distur-
bances of protein homeostasis, ER stress, and UPR [31, 
47], and more recently with compromised DNA repair [48]. 
Recently, expression of aggregation-prone truncated 1–120 
α-synuclein fragment caused evident, progressive neuronal 
loss accompanied by motor abnormalities [49]. However, 
significant cell death has not been consistently observed 
in many of the preclinical models based on α-synuclein 
overexpression [45]. Also, mice injected with PFFs, which 
induced profound aggregation of endogenous α-synuclein, 
have only demonstrated limited cell loss 180 days after 
PFF injection [16]. Only by simultaneous overexpression 
of α-synuclein in SN and inoculation with PFFs, a more 
robust phenotype demonstrating significant dopamine neu-
ron loss was observed [50]. Moreover, it remains an open 
question how well artificially induced α-synuclein misfold-
ing and aggregation can model LP observed in PD patients. 
Furthermore, the causative role of LP in PD patients has 
not been proven. Clinical data reveal a correlation between 
LP density and dopamine neuron loss [51]. However, when 
Fig. 2  ER stress and unfolded protein response (UPR) pathways. 
Activation of the unfolded protein response (UPR) is, in a normal 
state, prevented by interaction of GPR78 with UPR sensors inosi-
tol-requiring protein 1 (IRE1α), protein kinase RNA-like ER kinase 
(PERK) and activating transcription factor 6 (ATF6). Accumula-
tion of misfolded proteins leads to dissociation of GPR78 from the 
ER membrane located UPR sensors and activation of the UPR. Acti-
vated ATF6 translocates to the nucleus where it acts as a transcrip-
tion factor. IRE1α, a transmembrane serine-threonine kinase and 
endoribonuclease, degrades ER-localized mRNAs and splices mRNA 
of X-box binding protein 1 (XBP1) transcription factor, increasing 
its expression. In chronic and severe ER stress, hyperoligomerized 
IRE1α recruits TRAF2 and ASK1 by its cytosolic domain and this 
complex triggers apoptosis via p38 MAPK and JNK pathways fol-
lowed by enhanced transcription of pro-inflammatory genes. PERK 
phosphorylates eukaryotic translation initiation factor 2α subunit 
(eIF2α), reducing translation of most genes, concomitantly leading 
to increased translation of activating transcription factor  4 (ATF4). 
Moreover, PERK directly activates erythroid 2-related factor 2 (Nrf2) 
transcription factor. Together activated transcription factors increase 
expression of genes involved in protein folding, lipid biosynthesis, 
protein degradation, antioxidant response, and the UPR itself while 
the translation of other genes is reduced. Persistent block on transla-
tion can be detrimental to neurons. Additionally, if prolonged, UPR 
leads to upregulation and activation of pro-apoptotic genes
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analyzing brains with early LP outside the SNpc, and with-
out PD symptoms (putatively pre-symptomatic), a cell loss 
of up to 20% of SNpc dopamine neurons was found, despite 
the lack of LP in SNpc [51, 52]. Explanation of cells loss 
in SNpc devoid of LP might be that neuronal death was 
caused by misfolded α-synuclein monomers or oligom-
ers [53], while LP is an epiphenomenon or cell attempt to 
sequester aggregated proteins. In contrast, two recent studies 
suggest that the LP formation and sequestration of intra-
cellular organelles is driving neuronal death, rather than 
α-synuclein itself. Shahmoradian et al. [54] used Correlated 
Light-Electron Microscopy to evaluate the composition of 
LP in post-mortem human brains. Apart from α-synuclein, 
LPs were found to contain a large number of membranous 
structures, fragments of lysosomes, and mitochondria. An 
important role of membranous components of LP was cor-
roborated by a recent PFFs-based in vitro study [55]. The 
authors demonstrated that, triggered by PFFs, aggregates 
of endogenous α-synuclein transformed into Lewy body-
like structures 2–3 weeks after seeding. At this time, they 
started to include membranous components akin to human 
LP. Proteomic analysis of these mature aggregates demon-
strated enrichment of proteins belonging to mitochondria, 
ER, Golgi, endolysosomal pathways, and synapses [55]. 
Interestingly, partially damaged mitochondria present in 
these aggregates were capable of increasing oxidative stress 
and activating cell death pathways. There have also been 
enrichment in proteins linked with the ER stress response, 
suggesting that the UPR pathway might also be dysregu-
lated. Importantly, cell death was not observed before the 
transition of α-synuclein aggregates to an LP-like form and 
was only modest afterward [55].
Lastly, it is important to mention that α-synuclein might 
be our best bet for the early detection of PD. Protein mis-
folding cyclic amplification, a technique to amplify the con-
formational state of α-synuclein from patient samples, has 
recently been utilized to detect α-synuclein aggregates in 
cerebrospinal fluid samples [56] with high sensitivity. Since 
misfolded α-synuclein has been reported in peripheral tis-
sues [57], there is hope that it could serve as a marker for 
early detection of PD.
How do dopamine neurons die?
The current understanding of molecular pathways leading 
to dopamine neuron degeneration reveals a complex, often 
reciprocal interaction between specific physiology of dopa-
mine neurons, oxidative stress and mitochondrial dysfunc-
tion, proteostatic stress, disruption of autophagy–lysosomal 
pathway and accumulation of misfolded α-synuclein. Strong 
evidence links all these processes with dopamine neuron 
degeneration in PD [47]. However, we are missing the vital 
piece of the puzzle, which is understanding how dopamine 
neurons die in PD. Major cell death types include apopto-
sis, necrosis and autophagic cell death [58]. Apoptosis and 
autophagic cell death are classically programmed events, 
however in many cases it is now clear that necrosis can also 
be regulated to some extent by cells. Therefore, cell death is 
usually not just a catastrophic breakdown but orchestrated 
sequence of events that serves the survival of the whole 
organism [58, 59]. This gives hope that neuron demise can 
be delayed or prevented by blocking specific cell death path-
ways, at least before the cell reaches a point of no return such 
as mitochondrial membrane permeabilization [58].
Because of the dynamic nature of the cell death process 
and only transient activation of involved pathways [59], 
distinguishing different cell death types is difficult in post-
mortem samples. Nonetheless, many, but not all, studies on 
post-mortem samples revealed signs of apoptosis such as 
DNA damage and elevated activity of caspases, which are 
cysteine-containing proteases that cleave substrates after 
aspartic acid [60]. However, most of the data supporting 
the involvement of apoptosis in PD comes from preclinical 
cellular and animal models [60]. Findings from neurotoxin-
based models revealed a critical role of intrinsic mito-
chondrial apoptosis pathways in dopamine neuron death. 
The relevance of this pathway for humans is supported 
indirectly by the fact that genes linked with familial PD, 
namely DJ-1, PINK1, and Parkin, were shown to regulate 
the mitochondrial apoptosis pathway in neurotoxin models 
[60]. Apart from toxins damaging mitochondria, it was also 
proposed that apoptosis in dopamine neurons can be initiated 
by prolonged activation of the UPR due to the accumula-
tion of misfolded proteins and DNA damage through the 
p53-dependent pathway [60].
The involvement of autophagic cell death and necrosis in 
dopamine neuron death in PD is less clear than the involve-
ment of apoptosis. There are reports on autophagy in dying 
neurons in PD patients’ brains and neurotoxic models [60], 
however it is unclear if they account for autophagic cell 
death or might actually be the last attempt of a cell to prevent 
its demise [59]. Evidence for the involvement of necrosis 
comes from preclinical studies, where the same neurotox-
ins that induce apoptosis at low and moderate doses cause 
necrosis when administered at high doses [60].
Ultimately, it is important to remember that the majority 
of specific data on the death pathway of dopamine neurons 
comes from cellular and animal models under the assump-
tion that they resemble cell death pathways of human PD 
patients.
Can a current understanding of molecular 
pathology in PD guide us toward new therapies?
There is strong evidence for the involvement of all men-
tioned processes in the death of dopamine neurons in PD. 
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Multiple trials targeting specific mechanisms are under-
way (Table 1), so far however, such treatments have failed. 
The current state of knowledge does not allow us to find 
reasons for this failure unequivocally, but several options 
could be considered. Multiple pieces of evidence support 
the involvement of oxidative stress and mitochondrial fail-
ure, autophagy-lysosomal pathway disruption, proteostasis 
disruption, ER stress, and α-synuclein misfolding and aggre-
gation in PD pathology. Moreover, data shows that these 
cellular pathologies are interconnected, capable of inducing 
or aggravating each other, possibly causing a cascade of fail-
ures, as has also been proposed by other authors [12, 61–63]. 
However, current data do not clearly point to any specific 
pathological process as the main trigger of pathology nor as 
the main cause of dopamine neuron death. In fact, it is pos-
sible that no single mechanism can be pinpointed because 
no single mechanism for all patients [21], nor even maybe 
for all neurons in a single patient, exists. Because what we 
are observing are relatively downstream phenotypes, mul-
tiple pathways could exist to reach dopamine neuron death. 
From a therapeutic perspective, it means that drugs target-
ing pathological triggering mechanisms would have to be 
personalized for a given patient, basing treatment on yet 
unknown markers. However, current and past clinical trials 
for PD have been mostly targeting general patient popula-
tions, and this has been proposed as a reason for failure [21]. 
Moreover, even if a single mechanism is triggering pathol-
ogy for most patients, we would need to target it before it 
causes a cascading failure of other cellular systems. In con-
trast to mechanism-specific treatments, general anti-apop-
totic (assuming apoptosis as major cell death mechanism in 
PD) or survival-promoting treatments like NTFs, should be 
effective regardless of initial trigger and subsequent path of 
pathology progression (Fig. 1), as discussed below.
Special consideration should be given to the treatments 
targeting α-synuclein. We still do not know if α-synuclein is 
a causative factor in non-familial PD nor do we know mech-
anisms by which it contributes to cell death. Understanding 
the putative mechanism through which α-synuclein contrib-
utes to cell death is critical since it impacts which treatments 
might be effective, and which could even worsen disease 
progression. For example, we do not know if α-synuclein 
early oligomeric forms or rather Lewy bodies should be tar-
geted. If Lewy bodies are a sink for toxic oligomeric forms, 
their disruption could seal the fate of neurons. Growth of 
α-synuclein fibrils is also not sufficiently understood. If sec-
ondary nucleation is important in this process, treatments, 
such as antibodies capping α-synuclein, might actually pro-
mote the formation of smaller and presumably more toxic 
species through secondary nucleation. Nonetheless, several 
anti-α-synuclein antibodies and small molecule inhibitors 
of α-synuclein aggregation are currently tested in the clinic 
(Table 1). Drawing parallels to another neurodegenerative 
disorder—Alzheimer’s disease—where targeting pathologi-
cal protein aggregates have consistently failed in the clinic 
[64], targeting LP for the treatment of PD should be pre-
ceded by more systematic basic studies on the pathogenic 
mechanisms, because clinical trials planned on the basis 
of insufficient information may easily fail and discourage 
from pursuing this otherwise promising approach. Indeed, 
a recent press release about a clinical trial of Prasinezumab 
(NCT03100149), a humanized monoclonal antibody against 
α-synuclein, reported that the study did not meet a primary 
objective (https ://ir.proth ena.com/news-relea ses/news-relea 
se-detai ls/updat e-phase -2-pasad ena-study -prasi nezum ab-
prx00 2rg79 35).
Neurotrophic factors in preclinical studies
The rationale for NTF-based treatments of PD is their ability 
to both support the survival, regenerate axons, and increase 
neuronal function and connectivity. Therefore, they could 
not only protect remaining dopamine neurons but also stimu-
late their regeneration and capacity to make up for already 
lost cells. NTFs are secretory molecules important in neu-
ronal development, maintenance, and synaptic plasticity. 
Therefore, NTFs with the ability to promote the survival 
of dopamine neurons have been tested extensively in pre-
clinical models of PD. We have recently summarized the 
strengths, limitations, and future perspectives of PD models 
in a different review [65]. Most promising NTFs have been 
tested or are being tested in clinical trials. Probably the best-
studied NTFs in the context of PD are glial cell line-derived 
neurotrophic factor (GDNF) and another GDNF-family 
ligand neurturin (NRTN), brain-derived neurotrophic fac-
tor (BDNF), CDNF and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) (Fig. 3).
GDNF and GDNF‑family ligands
GDNF is an eponymous member of the GDNF fam-
ily ligands (GFLs), which also consists of NRTN, arte-
min (ARTN) and persephin (PSPN) [8]. GDNF was first 
described in the early nineties as a factor promoting sur-
vival of cultured midbrain dopamine neurons [66], thus not 
surprisingly, it was quickly tested as a potential therapeutic 
molecule for PD. GFLs are distant members of the trans-
forming growth factor β superfamily [8], and differently 
from other members of this family, GFLs signal through 
receptor tyrosine kinase RET [67]. However, this signal-
ing requires coreceptors: GDNF Family Receptor alpha 
1 to 4 (GFRα1-4). GFRα1-4 are usually glycosyl phos-
phatidylinositol (GPI) anchored at the plasma membrane 
or after cleavage of the GPI anchor are also present in a 
soluble form. GFLs do not bind directly to RET, but first to 
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Table 1  List of clinical trials targeting described pathological processes linked with dopamine neuron degeneration
Putative mechanism Treatment Description Trial identifier or refer-
ence
Trial phase Trial status
Preventing α-synuclein 
accumulation
ABBV-0805 Antibody against 
α-synuclein
NCT04127695 1 Pre-recruitment
AFFITOPE PD01/PD03 Vaccine against 
α-synuclein
NCT02618941, 
NCT02267434
1 Completed
MEDI1341 Antibody against 
α-synuclein
NCT03272165 1 Recruiting
BIIB054 Antibody against 
α-synuclein
NCT02459886 1 Completed
Prasinezumab Antibody against 
α-synuclein
NCT03100149 2 Active
Lu AF82422 Antibody against 
α-synuclein
NCT03611569 1 Recruiting
UB-312 Vaccine against 
α-synuclein
NCT04075318 1 Recruiting
Phenylbutyrate Small molecule increasing 
removal of α-synuclein 
from brain
NCT02046434 1 Active
Mannitol Small molecule, disrupts 
BBB and increase 
removal of α-synuclein 
from brain. Iinhibit 
α-synuclein aggregation
NCT03823638 2 Recruiting
NPT200-11 Small molecule inhibitor 
of α-synuclein misfold-
ing
NCT02606682 1 Completed
Reducing mitochondrial 
dysfunctions
Deferiprone Small molecule iron 
chelator
NCT02655315 2 Recruiting
CNM-Au8 Gold nanoparticles 
improve mitochondrial 
function, antioxidant
NCT03815916 1 Recruiting
CU(II)ATSM Small molecule improve 
mitochondrial function, 
antioxidant
NCT03204929 1 Active
UDCA Small molecule, ursode-
oxycholic acid, improve 
mitochondrial function
NCT03840005 2 Recruiting
Targeting PD linked genes BIIB094 Antisense oligonucleotide 
LRRK2
NCT03976349 1 Recruiting
DNL-151 Small molecule inhibitor 
of LRRK2
NCT04056689 1 Recruiting
DNL-201 Small molecule inhibitor 
of LRRK2
NCT03710707 1 Active
Ambroxol Small molecule enhancer 
of GBA activity
NCT02941822 2 Active
PR001A Gene threrapy, expression 
of functional GBA
NCT04127578 1/2 Recruiting
GZ/SAR402671 Small molecule enhancer 
of GBA activity
NCT02906020 2 Recruiting
1206 P. Chmielarz, M. Saarma 
1 3
Table 1  (continued)
Putative mechanism Treatment Description Trial identifier or refer-
ence
Trial phase Trial status
Neuroprotection and 
reduced inflammation
Exenatide Peptide agonist of GLP-1 NCT03456687 3 Recruiting
Semaglutide Peptide agonist of GLP-1 NCT03659682 2 Pre-recruitment
Liraglutide Peptide agonist of GLP-1 NCT02953665 2 Recruiting
Lixisenatide Peptide agonist of GLP-1 NCT03439943 2 Recruiting
NLY01 Peptide agonist of GLP-1 NCT04154072 2 Pre-recruitment
NPT520-3 Small molecule SLC22A8 
inhibitor, reduce nuero-
inflammation
NCT03954600 1 Recruiting
Neurotrophic action AAV2-GDNF Gene therapy, GDNF 
expression. Neurotrophic 
effects
NCT04167540 1 Recruiting
AAV2-GDNF Gene therapy, GDNF 
expression. Neurotrophic 
effects
NCT01621581 1 Active
NTCELL Encapsulated choroid 
plexus cells, produce 
neurotrophic factors
NCT01734733 1/2 Active
ITI-214 Small molecule PDE1 
inhibitor, increase cAMP 
levels, might increase 
NTFs production and 
function
NCT03257046 1/2 Completed
PDGF-BB Direct infusion of growth 
factor PDFG-BB,
NCT02236793 3 Ineffective
GDNF GDNF protein, monthly 
boluses to ventricle
Nutt et al. [128] 1/2 Completed, see text
GDNF GDNF protein, continuous 
infusion to putamen
Gill et al. [129] 1 Completed, see text
GDNF GDNF protein, continuous 
infusion to putamen
Slevin et al. [130] 1 Completed, see text
GDNF GDNF protein, continuous 
infusion to putamen
Lang et al. [133] 2 Completed, see text
GDNF GDNF protein, boluses to 
putamen
NCT03652363 2 Completed, see text
AAV2-NRTN Gene therapy, NRTN 
expression in putamen. 
Neurotrophic effects
NCT00252850 1 Completed, see text
AAV2-NRTN Gene therapy, NRTN 
expression in putamen. 
Neurotrophic effects
NCT00400634 2 Completed, see text
AAV2-NRTN Gene therapy, NRTN 
expression in putamen 
and SN. Neurotrophic 
effects
NCT00985517 1 Completed, see text
Neurotrophic and other 
actions
CDNF Protein infusion, general 
neuroprotective effects, 
axon regrowth, inter-
feres with α-synuclein 
oligomerization, reduces 
ER stress
NCT03295786 1/2 Active
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GFRα coreceptor and then the GFL-GFRα complex binds to 
and activates RET [67, 68]. GFRα1-4 determines the ligand 
selectivity of GDNF, NRTN, ARTN, and PSPN [8, 67, 68]. 
Binding of GDNF to GFRα1 and then to RET leads to RET 
dimerization, tyrosine autophosphorylation and activation of 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt, 
mitogen-activated protein kinase (MAPK) and Src pathways 
[8] (Fig. 3, middle). Additionally, GDNF and other GFLs 
can also bind to and signal through Neural Cell Adhesion 
Molecule (NCAM) activating Src pathway [69] (Fig. 3, mid-
dle). GDNF, NRTN, and ARTN can also bind and signal 
through heparan sulphate proteoglycan Syndecan-3 present 
at the cell surface [70] (Fig. 3, middle). RET and GFRα1 are 
expressed on SNpc dopamine neurons, however the main 
Table 1  (continued)
Putative mechanism Treatment Description Trial identifier or refer-
ence
Trial phase Trial status
Stimulate autophagy-
lyzosomal pathway
Nilotinib Small molecule c-Abl 
inhibitor, enhances 
autophagy
NCT03205488 2 Active, ineffective
K0706 Small molecule c-Abl 
inhibitor, enhances 
autophagy
NCT03655236 2 Recruiting
Reduce  Ca2+ fluctuations Isradipine Small molecule calcium 
channel blocker, reduces 
calcium fluctuations
NCT02168842 3 Active, ineffective
Blocks apoptosis KM-819 Small molecule FAF1 
inhibitor, inhibits 
apoptosis
NCT03022799 1 Completed
Fig. 3  Receptors and signaling modes of brain-derived neurotrophic 
factor (BDNF), glial cell line-derived neurotrophic factor (GDNF)-
family ligands (GFLs) and cerebral dopamine neurotrophic factor 
(CDNF). The mature form of BDNF exerts its neuroprotective effects 
through tyrosine kinase receptor B (TrkB), activating mitogen-acti-
vated protein kinase (MAPK), phosphatidylinositol-4,5-bisphos-
phate 3-kinase (PI3K)/Akt and phospholipase C-γ pathways (PLCγ) 
pathways. Alternatively, pro-BDNF can exert pro-apoptotic effects 
through p75 receptor. GFLs: GDNF, NRTN, ARTN and PSPN, act 
mainly through receptor tyrosine kinase RET together, requiring addi-
tional coreceptors GDNF Family Receptor alpha 1 to 4 (GFRα1-4). 
GDNF, NRTN, ARTN and PSPN bind to GFRα1 to 4, respectively. 
Binding of GFL-GFRα complex to RET activates MAPK, Src and 
PI3K/Akt signaling pathways. Additionally, GFLs can also signal 
through GFRα-NCAM and Syndecan 3 (with the exception of PSPN 
in the latter case). CDNF is an unconventional neurotrophic factor 
without a known membrane receptor. Putatively, CDNF can act both 
on the plasma membrane and intracellularly on the ER membrane. It 
exerts prosurvival effects attenuating ER stress and interacting with 
misfolded proteins
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physiological site of GDNF action is at their projections in 
the striatum [67]. GDNF infusions have been consistently 
demonstrated to be effective in animal neurotoxin models of 
PD [71]. It rescued 6-hydroxydopamine (6-OHDA)-induced 
lesions in rodents [72] and in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) both in rodents [73] and non-
human primates [74]. Importantly, GDNF was effective even 
when administered several weeks after neurotoxin treatment, 
demonstrating at least some potential at restoring already 
damaged dopamine neurons and their function [75]. NRTN, 
another GFL, has been shown to be similarly protective as 
GDNF in animal models of PD [76]. Both GDNF and NRTN 
were protective when administered as either a protein or 
expressed from viral vectors [77, 78]. Its effectiveness in 
animal models led to a quick move of GDNF to clinical tri-
als, findings of which will be summarized in the following 
section. It should be noted, however, that GDNF and NRTN 
were effective in mild and moderate neurotoxin models, 
whereas they showed weak or no neuroprotection when the 
nigrostriatal pathway lesion was severe. Furthermore, it was 
shown that GDNF failed to protect dopamine neurons from 
cell death induced by α-synuclein overexpression [79, 80]. 
This lack of effectiveness was presumably caused by the 
downregulation of RET and transcription factor Nurr1, both 
important for GDNF’s protective effects [81]. However, it 
remains disputed if findings from this animal model, where 
α-synuclein was overexpressed at high levels, are relevant 
for human patients [82].
BDNF
BDNF is a member of the neurotrophin family, originally 
described in the 1980s [83]. BDNF acts on cells by binding 
to either tyrosine kinase receptor (Trk) B or to low-affinity 
p75 neurotrophin receptor (p75), a member of tumor necro-
sis factor receptor superfamily [84]. BDNF can also bind 
to the TrkB-p75 complex. Survival promoting effects of 
BDNF are mediated by the TrkB receptor through activa-
tion of MAPK, Akt, and phospholipase C-γ pathways [84], 
while p75 receptors are mainly activated by BDNF precursor 
molecule, proBDNF triggering pro-apoptotic activity [84] 
(Fig. 3, left). Interestingly, p75 seems to be upregulated in 
neurodegenerative disorders and aging [85]. In human PD 
patients, BDNF levels were found to be decreased in the 
SNpc [86] and in the serum [87]. However, a quite surpris-
ing increase in the BDNF levels in later stages of the dis-
ease was also reported [88]. BDNF promotes the survival 
of dopamine neurons in vitro and in animal models of PD 
[89–91]. However, in contrast to GDNF and CDNF, BDNF 
was effective only when administered prior to neurotoxin, 
what suggest it would have to be administered at very early 
stages of PD. Altogether, it’s reasonable to assume that 
BDNF, while promising, will require the development of 
non-invasive administration strategies to very early stage 
patients as administering it to later-stage patients is currently 
not supported by preclinical evidence. Conversely, despite 
its links to PD and encouraging preclinical data supporting 
BDNF has not been tested in the clinic for the treatment of 
PD.
CDNF and MANF
CDNF and MANF form a novel, evolutionary conserved 
family of unconventional NTFs [92, 93]. Both proteins are 
paralogs with similar structures, different in amino acid 
sequence and in three-dimensional structure from all other 
NTFs [94]. They reside in the ER, where they play a role 
in maintaining protein homeostasis, and can be secreted in 
a calcium-dependent manner [95], but are also secreted in 
stress or cell injury. However, when expressed in cells or 
applied externally to stressed cells, they exert survival-pro-
moting effects on neurons and attenuate ER stress and the 
UPR [94] (Fig. 3, right). The mechanism of their action is 
still unknown, as are their putative receptor(s). Both MANF 
and CDNF were shown to be protective in vivo in 6-OHDA 
and MPTP rodent models of PD, both when administered 
as protein and when overexpressed from viral vectors [92, 
96–99]. Moreover, CDNF was shown to be effective in the 
non-human primate 6-OHDA model of PD [100]. The neu-
roprotective potential of CDNF and MANF has been sum-
marized in recent reviews [101, 102]. Overall, CDNF is at 
least as effective as GDNF [103] with the important advan-
tage of having better diffusion through the brain [96], and in 
addition to inhibiting neuronal apoptosis, also regulating ER 
stress and reducing the levels of pro-inflammatory cytokines. 
Better bioavailability would be important when infused into 
the human brain, much larger than that of rodents. Efficacy, 
desirable properties (diffusion) and a novel mechanism of 
action combining survival-promoting action with positive 
effects on protein homeostasis made CDNF an exciting new 
candidate for PD treatment. Indeed phase I-II clinical trial of 
CDNF in PD patients was recently initiated in three medical 
centers [102] (NCT03295786).
Importance of NTFs for dopamine neurons
While NTFs show protective effects on dopamine neurons, 
and may be required for their differentiation, it is not entirely 
clear whether they are necessary for dopamine neuron sur-
vival in normal physiological conditions. For example, 
BDNF and its receptor TrkB are not required for the survival 
of dopamine neurons, but BDNF plays a role in their matura-
tion [104]. As for GDNF, probably the most potent and most 
studied survival promoting NTFs for dopamine neurons, 
there have been some conflicting results about its neces-
sity for adult dopamine neuron survival [105–107], whereas 
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GDNF receptor RET is widely accepted to be necessary for 
their adult maintenance [108]. Interestingly, MANF knock-
out mice show a normal number of nigrostriatal dopamine 
neurons and their fibers [109] but in worms MANF seems 
to be required for long term maintenance of dopamine neu-
rons [110]. Also, the MANF-deficient fly [111] and zebrafish 
[112] show defects in the dopamine neuron system. Analy-
sis of the CDNF-deficient mice revealed that the number of 
dopamine neurons in SN and dopamine and its metabolite 
concentrations in the striatum are unaltered. However, an 
age-dependent functional deficit in the dopamine system 
function was found in  Cdnf−/− mice [7]. These mice develop 
an age-dependent loss of enteric neurons occurring selec-
tively in the submucosal but not in the myenteric plexus 
resulting in delayed gastric emptying, slowed colonic motil-
ity, and prolonged total gastrointestinal transit. The deficien-
cies of  Cdnf−/− mice, therefore, are similar to those seen in 
early stages of PD.
How do NTFs compare to other treatment 
strategies?
NTFs exert survival-promoting effects on dopamine neurons 
in diverse models, with at least some capability of promoting 
regeneration of axons and restoring dopaminergic pheno-
type. They seem to act through activating major pro-survival 
and anti-apoptotic pathways like MAPK, Src and AKT path-
ways. Consequently, NTFs have the greatest chance to work 
regardless of which pathological process is the major driver 
in a given patient, and should not require patient stratifi-
cation. Moreover, as they can exert anti-apoptotic action 
relatively downstream of pathology, they could also work 
at stages where blocking a single pathological process (i.e. 
oxidative stress) is not sufficient (Fig. 1). The anti-apoptotic 
action of NTFs might not be enough to save dopamine neu-
rons in PD since it is not unequivocal if apoptosis is the 
main cell death mode in PD. It is plausible that if NTFs 
block apoptosis, it will prolong the survival of neurons, but 
the damage would accumulate, and at some point, the neu-
rons will die by non-apoptotic death. Nonetheless, prolong-
ing survival of remaining neurons would still be of great 
benefit. If administered early after diagnosis, NTFs could 
prolong survival of the remaining 40–60% of dopamine 
cells which are still present at the onset of motor symptoms. 
Additionally, NTFs promote regeneration and function of 
dopamine cells. This could restore function in some neu-
rons which presumably lost their dopamine phenotype but 
are still alive. Moreover, increasing the function of remain-
ing neurons would compensate for lost ones. The beneficial 
effects would probably be even more pronounced if applied 
during the pre-symptomatic stage. Conversely, it is doubt-
ful that NTFs will exert significant clinical benefit when 
administered to late-stage patients with only a small fraction 
of dopamine neurons left. Additionally, there are some 
reports that NTFs could have a dual action—both survival-
promoting and affecting a specific pathological mechanism. 
Namely, CDNF can attenuate ER stress and regulate protein 
homeostasis. The effects of NTFs on specific pathologies 
would probably be most beneficial if applied very early in 
disease progression.
On the other hand, the effect of NTFs on non-motor 
symptoms might be limited. Effects of NTFs on the degen-
eration of non-dopaminergic neurons in PD will depend on 
both the presence of specific receptors and delivery mode. 
The most important GDNF receptor RET has limited expres-
sion in the brain, however, it is present on noradrenergic 
neurons, which are also profoundly affected in PD. BDNF 
and CDNF, in contrast, can affect more diverse neuronal 
populations. However, at present, delivery strategies aim 
at targeting dopamine neurons. In the future, blood–brain 
barrier permeable variants of NTFs or NTFs mimicking 
compounds might allow a peripheral delivery method. This 
would have both advantages of being acceptable to early-
stage patients or pre-symptomatic patients as well as affect-
ing multiple cellular populations.
Different approaches to stimulate NTF‑linked 
pathways
NTFs have mostly been applied either as a direct protein 
infusion or expressed from viral vectors. However, both of 
these approaches have significant drawbacks. Described 
NTFs do not pass through the blood–brain barrier, there-
fore requiring complicated stereotactic brain surgery to 
administer. At the same time, their diffusion in the brain 
is limited, and the production of NTF-based drugs can be 
costly [77]. Viral overexpression of NTFs allows continuous 
treatment without a need for repetitive injections. However, 
NTF gene therapy also requires a complicated intracranial 
administration. Apart from complicating clinical trials, the 
risk involved in surgical administration has played a role in 
limiting NTF clinical trials to relatively late-stage patients 
due to ethical concerns.
Several alternative approaches to protein or viral vector 
administration have been pursued to realize the therapeu-
tic potential of NTFs. Continuous delivery of NTFs into 
the brain could be achieved with encapsulated cell (EC) 
technology [113]. EC is based on the implantation of cells 
enclosed in semi-permeable membranes, which protect them 
from the host immune system while allowing them to release 
NTFs into the surrounding tissue and absorb nutrients. Such 
cells can be genetically engineered to secrete high levels of 
desired protein with the additional possibility of adding reg-
ulatory mechanisms, which would be difficult to fit into viral 
vectors. Moreover, EC devices can be designed so that it is 
possible to remove them from the brain in case of adverse 
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reactions. The use of EC implants also avoids problems with 
the transduction efficiency of viral vectors in the aged brain, 
which was recently implied for AAV2 vectors [114]. None-
theless, while EC implants still have to be delivered through 
a surgical procedure, and unless NTFs with good diffusion 
properties are utilized, they might require several deposi-
tion sites for NTFs to reach the entire putamen. Preclinical 
studies already demonstrated highly efficient delivery of 
GDNF by genetically engineered human ARPE-19 cells in 
rat striatum [115]. Also, ARPE-19 cells expressing CDNF, 
which have the advantage of better diffusion in the brain, 
were recently characterized by us [116]. Importantly, ARPE-
19-based EC implants have already demonstrated robust sur-
vival when implanted into Alzheimer patients’ parenchyma, 
demonstrating clinical maturity of the EC technology [113]. 
Another obvious (but not necessarily trivial) approach is to 
use small molecule agonists of NTF receptors (NTF mimet-
ics) [117, 118]. A blood–brain barrier permeable GDNF 
mimetic demonstrated protective effects on dopamine neu-
rons both in vitro and in vivo [118]. It is also possible to 
induce endogenous production of NTFs either through small 
molecules or interventions such as physical exercise [119]. 
Indeed, stimulation of BDNF production could explain some 
positive effects of physical exercise in PD [120]. Lastly, 
activating transcription factors downstream of NTFs, and 
putatively mediating their survival-promoting effects, could 
have therapeutic potential. It was shown that overexpression 
of Nurr1, which induces RET expression and is activated 
by GDNF, is protective for dopamine neurons [121]. Inter-
estingly, several reported small molecule activators target 
Nurr1, and could potentially be used in the clinic [122]. 
Nonetheless, while promising, these approaches have not 
yet been extensively validated, and (apart from intervention 
exercise), tested in the clinic for PD treatment. Approaches 
for the administration of NTFs or activation of NTF-linked 
pathways have been summarized in Table 2.
Neurotrophic factors in clinic
Due to promising preclinical evidence, several NTFs entered 
clinical trials for PD (Table 2), despite complications linked 
with their application in humans and uncertain mechanisms 
of action on brain dopamine neurons. However, complica-
tions linked with the delivery and insufficient understanding 
of disease etiology might have led to sub-optimal trial design 
and not meeting clinical endpoints.
GDNF
The first clinical trials for GDNF in PD started almost two 
decades ago. In these trials, GDNF was given monthly for 
over 8 months to 50 patients in a double-blind controlled 
trial design [123]. To simplify the delivery procedure, the 
drug was administered into the lateral ventricle, retrospec-
tively leading to concerns if GDNF was able to reach the 
site of action, considering its poor diffusion in the brain. No 
clinical improvement was observed, and even worse, at very 
high GDNF doses, side effects like nausea and weight loss 
were observed in some patients. Side effects were also attrib-
uted to a non-physiological site of delivery. In the subse-
quent trials, GDNF was delivered into the brain parenchyma, 
specifically into caudate putamen, correspondingly to pre-
clinical data. Two small open-label studies were made on 
5 PD patients [124] and 10 PD patients, respectively [125, 
126]. In these trials, GDNF demonstrated 30–60% improve-
ment in scores for motor activity and daily living. Improve-
ments were accompanied by increased markers of dopamine 
neuron function in the putamen, as assessed by PET [124]. 
Also, an increase in dopaminergic innervation was found in 
one post-mortem patient autopsy [127]. Following positive 
results in these two open-label trials, new placebo-controlled 
clinical trials were started [128]. GDNF in this new trial was 
administered continuously into the caudate putamen via the 
infusion pump. However, after 6 months of treatment, no 
difference from the placebo group was observed. Moreo-
ver, very surprisingly, some patients developed neutralizing 
antibodies for GDNF, which led to study withdrawal from 
safety concerns. Interestingly, one of the patients showed 
persistent benefits 3 years after treatment cessation, sug-
gesting effectiveness, at least in a subpopulation of patients 
[129]. It remains currently unclear how GDNF neutralizing 
antibodies could have arisen from intraparenchymal infu-
sions of the protein. Results from another placebo-controlled 
trial were reported recently [130, 131]. There, GDNF was 
administrated intraputamentally with a convection-enhanced 
delivery system once in a month for 6 months. While no 
significant improvement in UPDRS scores was observed, 
the study demonstrated the safety of GDNF infusion and an 
increase in dopamine neuron function in all GDNF treated 
patients, assessed through PET imaging. In line with the 
GDNF-induced increase in dopamine neuron activity, a post-
hoc analysis found nine (43%) patients receiving GDNF, 
but not placebo patients, demonstrated large motor improve-
ments in the OFF state. Lastly, an open-label gene therapy 
study with 25 patients receiving AAV2-GDNF vector into 
the putamen is currently ongoing (NCT01621581).
NRTN
NRTN was tested as a gene therapy in three clinical trials 
for PD. Initial open-label trials with intraputamental infu-
sion showed some improvements in UPDRS, but not in PET 
markers [132]. However, two subsequent double-blinded 
studies, one with putamental delivery [133] and the other 
one where AAV2-NRTN was delivered simultaneously into 
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both putamen and to SN [134] failed to meet clinical end-
points. Nonetheless, when patients were stratified by time 
from disease diagnosis, some benefits were observed in ear-
lier stage PD patients [133, 135]. The long-term effects of 
AAV-NRTN injections were recently described in a post-
mortem study of two patients 8 and 10 years after the virus 
injection [114], the former receiving injections to both puta-
men and SN and the latter to putamen only. The observed 
NRTN expression was limited to 3–12% coverage in the 
putamen, and 9–40% in SN, which probably contributed to 
the lack of clinical benefit. Significantly, in the areas where 
NRTN was expressed, it strongly increased dopaminergic 
innervation and dopamine cell markers, in putamen and SN, 
respectively, demonstrating long term benefits of NRTN. 
This indicates the capability of NRTN to protect and restore 
the function of dopamine neurons over a span of almost a 
decade. In the SN many protected neurons were positive for 
α-synuclein aggregates, suggesting that NRTN can protect 
neurons affected by pathological processes in PD. How-
ever, saving dopamine neurons in the SN have not improved 
innervation of the putamen, and conversely, administration 
of NRTN in putamen had only limited effects on the survival 
of dopamine neurons in the SN. This might be because at the 
time of administrations which was > 5 years after PD diagno-
sis, surviving dopamine cells in the SN might have already 
lost connection to the putamen, either due to degeneration 
of axons or disturbed axonal trafficking.
CDNF
The double-blind clinical phase I/II trials for CDNF ther-
apy for PD was started in autumn 2017 [102]. Importantly, 
CDNF therapy has the potential to have better coverage 
thanks to methodological improvements based on previ-
ous NTF studies and better brain diffusion of the protein. 
CDNF is delivered by a convection-enhanced delivery sys-
tem once a month for 6 months, which will be followed by 
an open-label extension period where all patients will be 
given CDNF. The first results of the 6 months study were 
announced in early 2020. Initial data suggest that CDNF 
is safe and shows promising signals of biological activity 
e.g. in dopamine transporter PET imaging in some patients, 
supporting the hypothesis of CDNF’s disease-modifying 
potential. The treatments continue and further results are 
expected in autumn 2020 (https ://heran tis.com/press _relea 
ses/heran tis-pharm a-plc-annou nces-topli ne-resul ts-of-phase 
-1-2-cdnf-trial /).
Difficulties, limitations and possible solutions
None of the completed double-blind clinical trials for NTF 
administrations met predefined endpoints for clinical effi-
cacy. The design of clinical trials for neuroprotection in PD 
remains challenging, conversely inadequate design might 
have contributed to the failure to demonstrate neuropro-
tection, as was discussed extensively by other authors [23, 
136]. Furthermore, post-mortem data strongly suggest that 
technical difficulties in delivering NTFs either as protein or 
viral vector and poor diffusion of GDNF and NRTN in the 
brain resulted in limited coverage of the targeted area [114]. 
Moreover, failed double-blind trials were conducted in late 
state patients. According to our current knowledge of PD 
progression, this very significantly limited chances of the 
success of these trials. Conversely, post-hoc analyses show-
ing more benefits in patients with less advanced PD [133] 
corroborate the notion that disease stage is a crucial factor 
contributing to chances of success.
Yet, despite failure to meet clinical endpoints, brain 
imaging and post-mortem data demonstrate the capability 
of NTFs to restore the function of the dopamine system and 
to protect dopamine neurons over the span of almost a dec-
ade in humans, despite clear signs of pathological processes 
inside protected cells [114]. This strongly supports the 
notion that NTFs, thanks to general survival- and function-
promoting effects, can effectively rescue dopamine neurons 
even with advanced stages of pathology. However, dopamine 
neurons must still be present in sufficient numbers, most 
likely with intact or at least functional axonal projections to 
the putamen to achieve clinical benefit.
Conclusions
Preclinical data strongly suggest complicated and possibly 
self-aggravating pathology in multiple intracellular pro-
cesses [12, 61–63]. Moreover, it seems plausible that the 
course of the disease differs between patients and might 
require drastically different treatments for different patient 
populations, targeting a patient-specific pathological path-
way [21]. Therefore, slowing PD progression with drugs 
targeting specific mechanisms might be possible only with 
the personalized approach at the very early, presympto-
matic stages of PD. So far none such single mechanism 
targeting drugs has demonstrated protective effects. In 
contrast, MAO inhibitors which have multiple mecha-
nisms of action, including general survival-promoting 
effects, possibly through NTF-linked pathways, demon-
strated hints of disease-modifying effects in double-blind 
clinical trials [22]. Conversely, NTFs with their general 
survival- and function-promoting effects on dopamine 
neurons could be effective, despite our lack of full under-
standing of disease etiology and without the need for 
patient-specific treatments. As discussed in this article, 
NTFs have effectively protected dopamine neurons in mul-
tiple preclinical PD models and showed some potential to 
restore the function of damaged dopamine neurons and 
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their axons. Moreover, despite failing to meet predesigned 
endpoints for clinical improvement, NTFs were able to 
enhance some aspects of dopamine system function and 
were able to improve innervation and increase survival of 
dopamine cells for almost a decade in PD patients [114, 
135]. Taking it all into account, failing to meet clinical 
endpoints does not invalidate NTFs as a treatment for 
PD but rather points toward technical challenges which 
limited the clinical benefit of treatment. These technical 
obstacles have already been discussed by other authors 
[4, 102], and include difficulties with the administration 
of proper dose, covering a large brain area, and recruit-
ment of early-stage patients—for which not only a safe 
but also minimally invasive administration method would 
be optimal. Additionally, conceptual redesign of clinical 
trials might help to detect even modest sings of NTFs’ 
effectiveness in late-stage patients, which in turn would 
help to convince regulatory bodies for trials in early-stage 
patients [23]. Importantly, solving these difficulties seem 
to lie within our current capabilities rather than requiring 
scientific breakthrough. Altogether, despite setbacks and 
remaining technical difficulties, NTFs remain front-runner 
candidates for disease-modifying therapies of PD.
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